Rafferty Asset Management
TSHA icon

Rafferty Asset Management’s Taysha Gene Therapies TSHA Stock Holding History

Rafferty Asset Management’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.05M Sell
154,706
-145,197
-48% -$859K ﹤0.01% 779
2026
Q1 		$1.34M Sell
299,903
-44,881
-13% -$209K 0.01% 698
2025
Q4 		$1.9M Buy
344,784
+104,999
+44% +$510K 0.01% 658
2025
Q3 		$784K Buy
239,785
+121,102
+102% +$343K ﹤0.01% 839
2025
Q2 		$274K Buy
+118,683
New +$258K ﹤0.01% 998
2025
Q1 		– Sell
-252,257
Closed -$436K – 1144
2024
Q4 		$436K Buy
+252,257
New +$523K ﹤0.01% 935

Other funds holding TSHA

Avoro Capital Advisors
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
RA Capital Management
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vestal Point Capital
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RTW Investments
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Rafferty Asset Management's TSHA Position: Q2 2026 in Review

Rafferty Asset Management reduced its Taysha Gene Therapies (TSHA) stake by 48% in Q2 2026, selling an estimated $859K and leaving 154,706 shares worth $1.05M. The position accounts for ﹤0.01% of the portfolio, ranked #779.

Rafferty Asset Management first reported a position in TSHA in Q4 2024 and has held it in 6 quarters since. The position peaked at $1.9M in Q4 2025. 208 funds tracked by Wall St. Rank hold TSHA as of Q2 2026.

  • Rafferty Asset Management held 154,706 shares of Taysha Gene Therapies worth $1.05M as of Q2 2026.
  • Rafferty Asset Management sold 145,197 Taysha Gene Therapies shares in Q2 2026, an estimated $859K.
  • Taysha Gene Therapies made up ﹤0.01% of Rafferty Asset Management's portfolio in Q2 2026, its #779 holding.
  • Rafferty Asset Management first reported a position in Taysha Gene Therapies in Q4 2024 and has held it in 6 quarters since.
  • Rafferty Asset Management's Taysha Gene Therapies position peaked at $1.9M in Q4 2025.
  • 208 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q2 2026.

Based on Rafferty Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.